|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 17 amino acid peptide from near the center of human SLPI.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||10 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is Daudi cell lysate.
PA5-20385 can be used with blocking peptide PEP-0502.
Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-kappa-B activation by inhibiting Ikappa-B degradation in the cytoplasm and competing for NF-kappa-B binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.